-
Mashup Score: 1Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition - 2 year(s) ago
Abstract BRAF/MEK inhibition remains standard of care for treatment of BRAF-mutated non–small cell lung cancer (NSCLC). Although common adverse events (AEs) have been reported through clinical trials and ongoing clinical practice, only a handful of reports have detailed unusual adverse events associated with these medications. This report presents a patient with BRAF-mutated NSCLC treated with…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Asian, Black patients with lung cancer face longer wait times to radiation treatment - 2 year(s) ago
Asian and Black patients with lung cancer experienced longer delays to radiation treatment than their white counterparts, according to study results published in Health Equity. “Our findings shed light on the potential presence and impact of structural racism on patients seeking cancer treatment,” Rajesh Balkrishnan, PhD, co-program director of population health and prevention
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Asian, Black patients with lung cancer face longer wait times to radiation treatment. https://t.co/BucgHozxgK @uvahealthnews #lungcancer #nonSmallCellLungCancer @UVA
-
-
Mashup Score: 2
Approval based on KEYNOTE-091 trial, which demonstrated a clinically meaningful improvement in disease-free survival with KEYTRUDA in these patients following
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Thrilled to announce that the KEYNOTE-091 trial led to @US_FDA approval of KEYTRUDA® as Adjuvant Treatment for Patients With Stage IB, II, or IIIA #NonSmallCellLungCancer (#NSCLC). 👉 https://t.co/7y5MMvkihR @Merck @etop_ibcsg #LungCancer #CancerResearch #ClinicalTrials https://t.co/d3VvCmbNhi
-
-
Mashup Score: 0FDA approves adjuvant Keytruda for non-small cell lung cancer - 2 year(s) ago
The FDA approved pembrolizumab as adjuvant treatment for patients with stage IB, stage II or stage IIIA non-small cell lung cancer after resection and platinum-based chemotherapy. The agency based the approval of pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, on results of the multicenter, triple-blind, randomized phase 3 KEYNOTE-091 trial.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA APPROVED: Adjuvant Keytruda for non-small cell lung cancer. https://t.co/AnpknkamIW #Keytruda @Merck #nonSmallCellLungCancer #HemOnc #OncAlert #MedEd #Cancer @US_FDA
-
-
Mashup Score: 5
Savolitinib plus osimertinib combination therapy has an acceptable safety profile and demonstrated antitumor activity in patients with MET-amplified, EGFR-mutated advanced NSCLC who experienced disease progression on prior EGFR tyrosine kinase inhibitor therapy.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the January issue of Cancer Discovery— Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in #EGFR-Mutated MET-Amplified #NonSmallCellLungCancer: TATTON, by @RHartmaier. https://t.co/8GO26EU1oe @AstraZeneca https://t.co/IjmKbDGBPW
-
-
Mashup Score: 0
The FDA granted accelerated approval to adagrasib for certain adults with non-small cell lung cancer.The indication applies to use of adagrasib (Krazati, Mirati Therapeutics) — a RAS GTPase family inhibitor — by adults with KRASG12C-mutated locally advanced or metastatic NSCLC who received at least one prior systemic therapy.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA APPROVED: Agrasib for certain adults with non-small cell lung cancer. https://t.co/0L9x8Widd6 #Agrasib #LungCancer @US_FDA #NonsmallCellLungCancer #Krazati @Mirati
-
-
Mashup Score: 1Hospital Utilization of Stereotactic Body Radiation Therapy and Rates of Surgical Refusal - 3 year(s) ago
Increasingly, stereotactic body radiation therapy (SBRT) is used for patients unfit for or unwilling to undergo operation for early-stage non–small cell lung cancer. It remains unclear how SBRT utilization has influenced patient refusal of surgical resection.
Source: The Annals of Thoracic SurgeryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients treated at high SBRT–using facilities are more likely to refuse surgical resection & to receive #RadiationTherapy after surgical refusal in #NonSmallCellLungCancer, per @JEFFsurgery's @BrianTillMD & @okusanyamd: https://t.co/r732AQURZ0 @annalsthorsurg #ResearchWednesday https://t.co/kPOBgNTP09
-
-
Mashup Score: 0
The FDA granted fast track designation to sapanisertib for treatment of certain patients with non-small cell lung cancer.The designation applies to use of the agent for adults with unresectable or metastatic squamous NSCLC whose tumors harbor nuclear factor erythroid 2-related factor (NRF2) mutations and who have received prior immune checkpoint inhibitor therapy and platinum-based chemotherapy.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA grants fast-track designation to #sapanisertib for lung cancer subset. https://t.co/qX0pQJDGG4 #lungcancer #nonsmallcelllungcancer #MedTwitter #MedEd #MedEducation #Oncology #OncAlert
-
-
Mashup Score: 0FDA approves Retevmo for lung cancer subset - 3 year(s) ago
The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.The indication applies to use of selpercatinib (Retevmo, Eli Lilly) by adults with locally advanced or metastatic RET fusion-positive NSCLC as detected by an FDA-approved test.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA APPROVED: Retevmo for lung cancer subset. https://t.co/s1U6ABuXK5 #MedTwitter #MedEd #MedEducation #Oncology #OncAlert #selpercatinib #Retevmo @Eli Lilly #lungcancer #nonsmallcelllungcancer #metastaticlungcancer
-
-
Mashup Score: 1Therapy for Stage IV Non–Small-Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guidelines Q and A - 3 year(s) ago
Non–small-cell lung cancer (NSCLC) is the leading cause of cancer deaths in the United States.1,2 Progress has been achieved recently for NSCLC, with screening; diagnosis and treatment; radiation therapy advancements including stereotactic ablative radiotherapy; novel research on the molecular drivers and nondriver alterations, leading to targeted therapies; and immunotherapies.3-7 Patients with…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP @ASCO Living Guidelines #QandA: Therapy Recommendations for Stage IV #NonSmallCellLungCancer with and without driver alterations and what clinicians need to know: https://t.co/OshVgYBJNt #NSCLC #LCSM @jaiyesi1 @ns_chd https://t.co/QkjH417u4G
-
𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐎𝐧𝐥𝐢𝐧𝐞: Unusual Adverse Events in a Patient With #BRAF-Mutated Non–Small Cell #LungCancer Treated With BRAF/MEK Inhibition - case report by @CatherineShuMD et al: https://t.co/KP8tyLIuzk #LCMS #NSCLC #NonSmallCellLungCancer https://t.co/qeHvxDi0IN